AI-generated · cited to primary sources · not investment advice
Dr Agarwal's Hea (544350) Nov 2025 Filing Analysis
Does management do what it says?
The company successfully relocated and upgraded its Whitefield, Bangalore facility in August 2024 from a secondary to a tertiary center, resulting in a 20% growth in revenue per month.
“recording a growth of more than 20% since we have relocated to this new 20,000”
The cash flow statement for the subsidiary (AEHL) confirms the receipt of INR 70 Cr. from the issue of equity share capital during H1 FY26.
“Proceeds from issue of equity share capital (including employee stock options”
Overall EBITDA margins for H2 FY26 are expected to remain at similar levels to H1 FY26 due to expansion pace.
“But in terms of the overall margins with the pace of expansion and with more Greenfields getting launched, the overall margins on a percentage basis should be on similar levels as to whatever we have reported on for H1, Tushar”
Expectation of 4.5% to 5% growth in realization due to premiumization in cataract surgeries.
“We are seeing a good amount of increase in premiumization, and that has been around 4.5% to 5% for this quarter. We hope to continue with that kind of growth over the next few quarters”
The company plans to significantly expand its presence in the Delhi-NCR market over the next 12 months.
“Building on this momentum, we plan to significantly expand our presence rapidly in the Delhi-NCR market over the next 12 months”
See the full cited Management analysis of Dr Agarwal's Hea
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.